Group 1 - The core point of the article is that Zhongji Changshou Science (00767) announced that the Hong Kong court has approved and ordered the withdrawal of the petition previously submitted by the petitioner on August 6, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 最新進展公告 撤回清盤呈請 茲提述中基長壽科學集團有限公司（「本公司」）於二零二五年七月十一日及二零二五 年七月二十九日刊發有關針對本公司的法律費用清盤呈請（「清盤呈請」）的公告（「先 前公告」）。除另有指明外，本公告所用全部詞彙應與先前公告所採用者具有相同涵 義。 本公司律師告知，香港法院已於二零二五年八月六日批准及下令呈請人先前提交的 同意傳票，針對本公司的呈請現已撤回。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 中基長壽科學集團有限公司 主席兼執行董事 閆立 香港，二零二五年八月八日 – 1 – 於本公告日期，董事如下： 執行董事 閆立先生 （主席） 閆一帆先生 （行政總裁） 李小雙先生 曹衆女士 獨立非執行董 ...

Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the world's largest international autologous immune cell bank and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - It is the only clinical cell bank in Asia registered with the FDA for both immune cells and stem cells, ensuring compliance with international standards for cell management [2] Group 3 - The Comprehensive Cell Bank began operations on November 17, 2018, and possesses patented technologies in cancer early screening, NK cells, stem cells, and cartilage cells, along with 22 advanced medical testing platforms [3] - The company can provide services to 300,000 people globally, with potential revenue exceeding HKD 30 billion from immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [3]

Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the largest international autologous immune cell bank in the world and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - The bank addresses the global challenge of insufficient international standard cell quantities and ensures safe and effective applications, positioning itself as a leading international cell transformation application platform [2] Group 3 - Since its operation began on November 17, 2018, the Comprehensive Cell Bank has developed patented technologies in cancer early screening, NK cells, stem cells, and chondrocytes, and operates 22 advanced medical testing platforms [3] - The bank can provide services to 300,000 people globally, focusing on immune cell storage, cancer early screening, longevity medical testing, and cell therapy research and development, with potential revenue exceeding HKD 30 billion [3]

Group 1 - The company, Zhongji Changshou Science (00767.HK), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the largest international autologous immune cell bank in the world [1][2] - Comprehensive Cell Bank is recognized as the only FDA, AABB, PIC/S cGMP, ISBER-IRL, FACT, CAP, and ISBT 128 compliant international clinical cell bank, addressing the global shortage of standard cells and ensuring safe and effective applications [1][2] Group 2 - The Comprehensive Cell Bank is the only FDA-registered immune cell and stem cell bank in Asia, meeting international standards for cell management and storage [2] - The facility, located in Hong Kong, has been operational since November 17, 2018, and possesses patented technologies for cancer early screening, NK cells, stem cells, and chondrocytes, along with 22 advanced medical testing platforms [2] - The target company aims to provide services to over 300,000 individuals globally, with potential revenue exceeding HKD 30 billion from its offerings in immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 – 1 – 排他期 訂約各方應真誠信實地與對方磋商，以確保訂立有關可能收購事項之正式買賣協議 （未必一定會訂立）（「最終協議」），惟無論如何應於由諒解備忘錄日期起計滿六 十(60)天當天或之前（「排他期」）（或諒解備忘錄訂約各方可能協定之較後日期）訂 立。訂約各方進一步協定，於排他期內不得就任何性質相近之交易或合作與任何第 三方磋商或訂立任何協議。 盡職審閱 （於百慕達註冊成立之有限公司） （股份代號：767） 有關可能收購事項之諒解備忘錄 本公告乃中基長壽科學集團有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨 條例第XIVA部項下內幕消息條文發表。 諒解備忘錄 本公司董事（「董事」）會（「董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 內幕消息 有關二零一五年收購代價可換股票據之 法律程序公告 本公告由中基長壽科學集團有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.09條及第13.25條以及香港法例第571章《證 券及期貨條例》第XIVA部刊發。 茲另提述(i)中基長壽科學集團有限公司（「本公司」）日期為二零一五年九月二十九日 之通函（「收購事項通函」），內容有關本公司收購「財加P2P融資貸款平台業務」（「收 購事項」），以及收購事項代價（「代價」）2,400,000,000港元（可予調整）須以發行本金 額為2,400,000,000港元之不可贖回可換股票據（「本金可換股票據」）支付；及(ii)本 公司日期為二零一七年七月 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | ...

Group 1 - Heartway Medical-B (06609.HK) expects a net profit of no less than RMB 40 million for the six months ending June 30, 2025, a significant turnaround from a net loss of approximately RMB 5.1 million for the corresponding period ending June 30, 2024 [1] - The anticipated profit and performance improvement are primarily due to business growth, leading to increased revenue and a decrease in overall expenditure ratio compared to the corresponding period [1] Group 2 - Baoshan International (03813.HK) expects a mid-term net profit of approximately RMB 187.6 million, a year-on-year decrease of 44.1% [2] - Baio Family Interaction (02100.HK) anticipates a mid-term profit increase of approximately 134.9% to 141.6% [2] - Skyworth Group (00751.HK) warns of an expected mid-term post-tax profit decline of about 50% year-on-year [2] Group 3 - China CNR Corporation (01766.HK) recently signed a significant contract worth approximately RMB 32.92 billion [2] - China Power (02380.HK) reported a total electricity sales volume of 11.299 million megawatt-hours in June, a year-on-year decrease of 5.04% [2]

Core Viewpoint - Zhongji Changshou Science (00767) has entered into a memorandum of cooperation with Haoshiduo (Shenzhen) Biotechnology Co., Ltd. to collaborate on longevity detection and management services, aiming to provide longevity-related products and health consultation services in the health industry [1][2] Group 1 - The cooperation will involve Zhongji Changshou's subsidiary, Hongfeng Development, providing product services and management system support, while Haoshiduo will supply domestic customer resources and market sales channels [1] - Haoshiduo is an innovative biotechnology company engaged in health, biotechnology research and development, and artificial intelligence application software development, with strong customer base and market expansion capabilities [1] - The board believes that the health and longevity science market has broad prospects, as wealthy customers globally are increasingly willing to invest in longevity science applications to enhance their overall health and immune status [1] Group 2 - The memorandum aligns with the group's strategy for developing longevity science business and is expected to benefit future business growth [2] - The board is confident that the cooperation will enhance the group's layout in the longevity science diagnostics and medical services sector, opening new revenue sources in longevity science [2] - The aim is to achieve more stable and sustainable revenue growth for the group in the long term [2]